Skip to main navigation

Live - Top Menu

  • Clinical Trials
  • Investors & Media
  • Careers
  • Contact Us
Menu
Close

Main navigation

  • Our Focus
  • Our Research
  • Our Medicine
  • Our Story
Home > Investors & Media > Press Releases
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Press Releases

Press Releases

Mar 02, 2023
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
U.S. Ocaliva ® net sales of $77.2 million and $285.7 million for the fourth quarter and full year 2022, representing 13% and 10% growth over the prior year Worldwide Ocaliva ® non-GAAP adjusted net sales of $343.8 million for the full year 2022 As of December 31, 2022 , Company has cash, cash
Read More
Feb 27, 2023
Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023
MORRISTOWN, N.J. , Feb. 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and
Read More
Feb 23, 2023
Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
MORRISTOWN, N.J. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full-year 2022
Read More
Jan 19, 2023
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study demonstrating OCA’s improvement in liver fibrosis without worsening of NASH PDUFA target action date set for June 22, 2023 MORRISTOWN, N.J. , Jan.
Read More
Jan 05, 2023
Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
MORRISTOWN, N.J. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and
Read More
Jan 04, 2023
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
MORRISTOWN, N.J. , Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid
Read More
Dec 23, 2022
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with nearly 1,000 patients on study drug for 4 years MORRISTOWN, N.J. , Dec.
Read More
Dec 08, 2022
New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease
MORRISTOWN, N.J. , Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, is pleased to share that The American Journal of
Read More
Nov 22, 2022
Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022
MORRISTOWN, N.J. , Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso , President and
Read More
Nov 07, 2022
Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
First-in-human data shared at The Liver Meeting ® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults Company announces severe alcohol-associated hepatitis (sAH), a disease with no approved therapies, as its lead indication for INT-787 Company initiates Phase 2a
Read More

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
    • Financial Information
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Contact Us

Shareholder Tools

  • Email Alerts
  • Download Library
  • RSS
  • Print
  • Share
  • Facebook
  • LinkedIn
  • Twitter

Live - Footer Menu

  • Privacy Policy
  • Privacy Shield Policy
  • Corporate Compliance
  • Terms of Use
  • Contact Us
  • Cookie Preferences
305 Madison Avenue|Morristown, NJ 07960|T: 844-782-ICPT
© 2023 Intercept Pharmaceuticals, Inc.